scholarly journals Role of Brain Natriuretic Peptide assay in identifying children with pneumonia complicated by congestive cardiac failure

2018 ◽  
Vol 4 (2) ◽  
pp. 182-188
Author(s):  
Wilson E. Sadoh ◽  
Wilson O. Osarogiagbon
Keyword(s):  
Developing Countries ◽  
Respiratory Distress ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Cardiac Failure ◽  
Congestive Cardiac Failure ◽  
Morbidity And Mortality

Background: Pneumonia in children is a leading cause of morbidity and mortality in developing countries. It is often complicated by Congestive Cardiac Failure (CCF), with some of the symptoms similar to those of pneumonia. Brain Natriuretic Peptide (BNP) assay can differentiate cardiac from respiratory-related causes of respiratory distress. Objective: To determine the role of BNP in differentiating isolated pneumonia from pneumonia complicated by CCF. Methods: Over a 12-month period, consecutive children with radiologically-confirmed pneumonia were recruited for the study. Those with complicating CCF were noted. All the children had blood BNP assay done by ELISA, prior to treatment. Biodata was obtained and the children were grouped into those with isolated pneumonia and those with pneumonia complicated by CCF. Results: Fifty children were recruited; of these 26 (52.0%) had isolated pneumonia while 24 (48.0%) had pneumonia with CCF. The median age of the children was 6 months. The median BNP values for the isolated pneumonia group (229.4 ng/l), was significantly lower than that of pneumonia complicated by CCF group (917.3 ng/l); (p = 0.007). ROC showed that a BNP value >550ng/l could identify children with pneumonia complicated with CCF from those with isolated pneumonia with a sensitivity of 70.4% and specificity of 63.4%. Conclusion: A BNP assay prior to treatment of >550ng/l can differentiate children with pneumonia complicated with CCF from those without CCF.

How to use N-terminal pro-brain natriuretic peptide (NT-proBNP) in assessing disease severity in bronchiolitis

2019 ◽  
Vol 105 (5) ◽  
pp. 282-288 ◽  
Author(s):  
Keir Dan Edwards ◽  
Mark Peter Tighe
Keyword(s):  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Cardiac Failure ◽  
Cardiac Disease ◽  
Respiratory Compromise ◽  
Conflicting Evidence ◽  
Congenital Cardiac Disease ◽  
Viral Illness ◽  
Respiratory Causes

Bronchiolitis is a common viral illness which can lead to severe respiratory compromise and can coexist with or mask cardiac failure. Brain natriuretic peptide (BNP) and the inactive portion of its pro-hormone: N-terminal pro-BNP (NT-proBNP) are excreted in response to cardiomyocyte stretching and are established biomarkers in cardiac failure. Here, we discuss the technicalities of NT-proBNP testing and review available evidence regarding NT-proBNP testing in bronchiolitis. We identified and appraised seven studies assessing the role of BNP or NT-proBNP as biomarkers of bronchiolitis severity, in children with and without underlying congenital cardiac disease. One study of 76 children with dyspnoea showed that the median NT-proBNP level in children with cardiac failure was 7321 pg/mL vs 241 pg/mL in children with a respiratory cause of dyspnoea vs 87.21 pg/mL in healthy controls (p<0.05). A cut-off of 726 pg/mL could aid differentiation between cardiac and respiratory causes of respiratory distress. Other evidence showed a positive correlation between BNP levels and bronchiolitis severity, and that raised BNP can predict acute heart failure in children with congenital cardiac disease presenting with bronchiolitis. However, most studies consisted of small cohorts with conflicting evidence between them. Furthermore, several studies assessed BNP rather than NT-proBNP directly. BNP has a shorter half-life, which may affect analysis. In conclusion, NT-proBNP is a rapid and inexpensive test with the potential to be a useful biomarker in severe bronchiolitis and cases complicated by acute cardiac failure. However, studies with larger cohorts are required to better establish this role.

C-Reactive Protein, Interleukin 6, and N-Terminal Pro-Brain Natriuretic Peptide Following Cardioversion of Atrial Fibrillation: Is There a Role of Biomarkers in Arrhythmia Recurrence?

Angiology ◽  
2010 ◽  
Vol 62 (4) ◽  
pp. 310-316 ◽  
Author(s):  
Stavroula N. Psychari ◽  
Dionyssios Chatzopoulos ◽  
Efstathios K. Iliodromitis ◽  
Thomas S. Apostolou ◽  
Dimitrios T. Kremastinos
Keyword(s):  
Atrial Fibrillation ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Interleukin 6 ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals Brain natriuretic peptide: Diagnostic potential in dogs

2009 ◽  
Vol 63 (5-6) ◽  
pp. 381-392
Author(s):  
Ljubica Spasojevic-Kosic
Keyword(s):  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Natriuretic Peptides ◽  
Arterial Disease ◽  
Cardiac Insufficiency ◽  
Everyday Clinical Practice ◽  
Coronary Arterial Disease ◽  
Diagnostic Potential ◽  
Adequate Method

The endocrine role of the heart is evident in the secretion of noradrenaline and natriuretic peptides. The secretion of natriuretic peptides presents a useful mechanism for different conditions of cardiac dysfunction. Brain natriuretic peptide (BNP) has been accepted in human cardiology as a biomarker for cardiac insufficiency and coronary arterial disease. The specificity of the BNP structure is specie-specific, so that the testing of diagnostic and prognostic potential in dogs requires the existence of a test that is a homologue for that animal specie. The existence of an adequate method for measuring BNP concentration makes possible its implementation as a screening test in everyday clinical practice. .

Brain natriuretic peptide: the reason of respiratory distress is heart disease or lung disease?

2015 ◽  
Vol 33 (5) ◽  
pp. 697-700 ◽  
Author(s):  
Taylan Sahingozlu ◽  
Ulaş Karadas ◽  
Kayi Eliacik ◽  
Ali Rahmi Bakiler ◽  
Nihal Ozdemir Karadas ◽  
...  
Keyword(s):  
Heart Disease ◽  
Respiratory Distress ◽  
Brain Natriuretic Peptide ◽  
Lung Disease ◽  
Natriuretic Peptide

scholarly journals The role of zinc supplementation for diarrhoea in children: a critical review

2019 ◽  
Vol 18 (2) ◽  
pp. 190-195
Author(s):  
Wulandari Berliani Putri ◽  
Syaefudin Ali Akhmad ◽  
Sufi Desrini
Keyword(s):  
Developing Countries ◽  
Zinc Supplementation ◽  
Controlled Trial ◽  
Medical Science ◽  
Morbidity And Mortality ◽  
High Morbidity ◽  
Double Blind ◽  
Sanitation And Hygiene ◽  
Study Selection

Background: Nearly 1.7 million children suffer from diarrhoea and around 760,000 die each year. The high prevalence of diarrhoea in the developing countries is closely related to lack of safe drinking water, inadequate sanitation and hygiene, and poor health and nutritional status. These environmental conditions facilitate the spread of infectious disease easily. The great morbidity and mortality of this preventable and treatable disease raise concern on how to save children from this fatal disease by improving management of diarrhoea. Several studies suggest that zinc deficiency contribute towards high morbidity and mortality in diarrhoea. Further, there is an area of uncertainty regarding how significant zinc supplementation will help to reduce the duration and severity of diarrhoea in children compared to the diarrhoea management without zinc? Objective: To critically analyse the current evidences of zinc supplementation in diarrhoea. Data Sources: Keywords searching through MEDLINE Ovid database and additional references from retrieved articles. Study Selection: Limited to randomized controlled trial(RCT) study design and systematic review studies which were conducted from 2006 to 2016. However, there is one prospective cohort study included as it is a follow-up of subjects who participated in the previous double-blind randomized placebo-controlled trial. Data Synthesis: This review involves a summary of 10 articles that have been appraised on their relevance in evaluating the role of zinc in reducing severity and duration of diarrhoea in children. Further, the literature found is synthesised through method used in the studies and the effectiveness of zinc therapy Conclusion: Zinc is relatively safe to be used and it can improve diarrhoea management especially in developing countries. Bangladesh Journal of Medical Science Vol.18(2) 2019 p.190-195

Responses of vasoactive hormones in congestive cardiac failure

1987 ◽  
Vol 65 (8) ◽  
pp. 1706-1711 ◽  
Author(s):  
C. I. Johnston ◽  
L. F. Arnolda ◽  
K. Tsunoda ◽  
P. A. Phillips ◽  
G. P. Hodsman
Keyword(s):  
Heart Failure ◽  
Cardiac Failure ◽  
Atrial Natriuretic Factor ◽  
Peripheral Resistance ◽  
Congestive Cardiac Failure ◽  
Renin Angiotensin ◽  
Natriuretic Factor ◽  
Vasoactive Hormones ◽  
Atrial Natriuretic

Congestive cardiac failure causes activation of various neurohumoral responses that increase total peripheral resistance and promote salt and water retention. These effects increase blood pressure and organ perfusion in the short term, but ultimately cause further cardiac decompensation by increasing ventricular afterload and cardiac work. The role of the renin–angiotensin–aldosterone system and the catecholamines is partially understood, and blockade of these systems as a treatment of heart failure is now established. The role of vasopressin in heart failure is more controversial, but there is now compelling evidence that vasopressin may have important vasoconstrictor actions in addition to its fluid retaining properties. Atrial natriuretic factor is a newly described cardiac hormone released from the atrium. Atrial natriuretic factor causes natriuresis, diuresis, vasodilatation, suppression of thirst, and suppression of both renin and aldosterone. These actions largely counteract the effects of the renin–angiotensin system and vasopressin. Plasma atrial natriuretic factor has been reported to be markedly elevated in human and experimental heart failure, and may act to limit the neurohumoral response to reduced cardiac output. This review summarizes our understanding of the vasoactive hormones and reports experimental evidence supporting a pathophysiological role for vasopressin and atrial natriuretic factor in congestive cardiac failure.

Sign in / Sign up

Export Citation Format

Share Document